A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr
A phase 1/2 trial of AZD6621 in prostate cancer, run by AstraZeneca, now recruiting.
Overview
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07192614 by AstraZeneca, with 52 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-03-29. Interventions recorded: AZD6621. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer
Phase
Phase 1/2
Sponsor
AstraZeneca
Registry
Enrolled
52